Day 3Wednesday, 6 November 2024 - CET/CEST (Cent Europe Summer, GMT+2)

Location: Exhibit Stage

SapiensBio is a small data-driven technology-based drug discovery company with Headquarters in South Korea and an office in the USA. The company focus on the discovery of novel drug candidates for the treatment of severe (life threatening) diseases where there is a clear unmet medical need. We are integrating machine learning technology with wet lab experimental work to support the identification of novel therapeutic targets and to create novel chemical matter with drug like properties that can rapidly be converted in clinical candidates.

Location: Exhibit Stage

We at ingineeon develop the tools to form an unbeatable alliance with the most precise, efficacious and lasting force against diseases: our immune system. With our cytokine-based immunotherapeutics we can precisely modulate immune responses. This will allow for a therapeutic breakthrough in immuno-oncology, infectious diseases and autoimmunity. Our pipeline comprises first-in-class biologics as well as a cytokine-based platform biotechnology for advanced therapy medicinal products. Each of our compounds is based on scientific breakthrough innovations. Each of them has an unique Mechanism of Action with a therapeutic breakthrough potential in the respective indication. After generating a promising pipeline, a strong IP portfolio and promising data from our preclinical patients studies we are ready for the next big step: spin-off from the Technical University of Munich to become a clinical stage company in the coming few years.

Location: Exhibit Stage

PartitionBio is a start-up R&D company that is active in the biotechnology & pharma sectors. The company has been operating since 2022 and is incorporated as a private limited company (UK company number 13421275). PartitionBio has its offices and laboratories on the Chesterford Research Park near Cambridge, and currently employs 9 full-time staff. Company vision and scientific background The past decade has seen an explosion of scientific insight into the role that biomolecular condensates play in biology, as well as into the physicochemical principles underlying their formation by liquid-liquid-phase-separation (LLPS) of biomolecules. PartitionBio’s vision is to translate this emerging understanding into novel biomedical applications, particularly in the therapeutics space. The company’s initial focus is on the identification of formulations that generate biomolecular condensates capable of enriching drug cargos and of delivering them across the membranes of target cells. The company aims to develop its recent discoveries in this area into a viable platform approach for the delivery of hard-to-deliver therapeutics (specifically large biology drugs) in a clinical context. Team & capabilities The team of scientists at PartitionBio combines expertise in a range of biomedically relevant disciplines, including synthetic chemistry, protein engineering, condensate & cell biology and high-content screening microscopy. We use this know-how to design, generate and interrogate libraries of peptidomimetic oligomers to discover novel condensate-forming formulations. Leadership Dr Niall Armes is the scientific founder of PartitionBio. In previous ventures TwistDx and Biocrucible he has pioneered the use of biomolecular condensates for the acceleration of enzyme kinetics in in vitro reaction systems, particularly for the isothermal amplification of DNA. PartitionBio is led by Managing Director Dr Olaf Piepenburg, formerly CSO of TwistDx

Location: Exhibit Stage

A novel personalized diagnostic test for optimal cholesterol-lowering therapy.

Moncyte is the next level decision making tool to revolutionize the treatment of high cholesterol and bring more health to patients.

Location: Exhibit Stage

LincSwitch is a drug discovery platform company specializing in long non-coding RNAs (lncRNAs). Our platforms explore the dark genome, emphasizing phenotypic outcomes, with the objective of achieving rapid and robust regulation of pharmaceutically relevant target genes. LincSwitch was co-founded this year by CEO Andrew Sandford, former President of ElevateBio Basecamp; Marvin Caruthers, PhD, Distinguished Professor at CU Boulder and co-founder of Amgen and Applied Biosystems; John Rinn, PhD, Professor at CU Boulder; and Olivia Scharfman, former Principal at SALT Fund.

Location: Exhibit Stage

Location: Exhibit Hall Stage

Experience how a few deep breaths and simple stretches can de-stress you in just a few minutes.

Take a moment to exhale and move your body.

Calm your mind and feel the difference.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Standing exercises only.

Sustainability Focus Area: Social Responsibility